Assyro AI

FDA Orange Book · active-ingredient family

Florbetaben f-18

Florbetaben f-18 is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:NEURACEQ · NDA 204677

1

Brand (NDA)

0

Generics (ANDA)

2

Listed patents

0

Exclusivity periods

Brand (NDA) products · solution

ProductApplicantApplicationTEApproved
NEURACEQRLDLANTHEUSNDA 204677Mar 19, 2014

Listed patents (2)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7807135Mar 18, 2029in 2 yr 9 mo
SubstanceProductU-1497
9308284Jul 14, 2032in 6 yr 2 mo
Product

Florbetaben f-18 — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.